Avantor (AVTR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Avantor

NYSE•Healthcare•Medical Instruments & Supplies

$14.71-0.18(-0.01%)Market open

Market Cap

$10.72B

P/S

1.6x

P/B

1.9x

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

How this company scores

AverageMetricSide Score: 40/100

Strongest: Cash & Earnings Quality (16/25); weakest: Growth (5/25).

Profitability7/25

Growth5/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality16/25

Strengths

Cash-backed earningsConsistent free cash flowImproving marginsNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 13.3x5y range 13.3x – 65.8x

Currently below its 16-quarter median.

P/S · 1.6x5y range 0.8x – 3.3x

Currently near its 20-quarter median.

P/B · 1.9x5y range 0.9x – 7.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 130.4% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $10.72B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $6.56B
Q. Revenue: $1.69B
TTM EBITDA: $117.30M
TTM Op. Income: $-301.10M
Q. Op. Income: $121.80M
TTM Net Income: $-578.00M
Q. Net Income: $38.10M
EPS: $0.06
Shares Out.: $676.20M

$6.56B in TTM revenue declined 1.6% YoY, reaching $1.69B last quarter. TTM EBITDA of $117.30M and TTM operating income of $-301.10M show growth is flowing through to the bottom line. However, net income is negative at $578.00M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 2% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 31.7%
EBITDA Margin: 13.4%
Op. Margin: 7.2%
Net Margin: 2.3%

Op. margin of 7.2% is down 0.5% YoY — costs are rising relative to revenue. Net margin at 2.3% and gross margin of 31.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 6% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.6x
P/B Ratio: 1.9x

P/S of 1.6x and P/B of 1.9x. P/S is low relative to typical market levels. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $11.60B
Cash: $306.80M
Long-Term Debt: $3.66B
Book Value: $5.63B
D/E Ratio: 0.7
Debt/EBITDA: 16.1

With $11.60B in assets and $3.66B in long-term debt, D/E is 0.7and book value is $5.63B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $178.20M
TTM Free Cash Flow: $454.70M
FCF Margin: 6.9%
FCF / Net Income: -0.8

TTM FCF of $454.70M on $178.20M in operating cash flow. The FCF / Net Income ratio of -0.8x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 18% — an improving trend.